<!DOCTYPE html>
<html lang="en" dir="auto">

<head>
<head>
    <title>cardiovascular medicine</title>
    <meta charset="utf-8">
    <meta name="description"
        content="Website meta description for google search results go here" />
    <meta name="dc.relation" content="https://trxiv.yorks0n.com" />
    <meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">
    <meta name="theme-color" content="#1A94D2" />

    

    
    
    
    <link rel="stylesheet" href="/css/main.min.css" media="screen">

</head>


<meta charset="utf-8">
<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">
<meta name="robots" content="index, follow">
<title>cardiovascular medicine | TRxiv2</title>
<meta name="keywords" content="">
<meta name="description" content="The persistent underrepresentation of patients with chronic kidney disease in cardiovascular trials: a systematic review and evidence map of exclusion and outcomes
Authors: Colombijn, J. M. T.; Idema, D. L.; van Beem, S.; Blokland, A. M.; van der Braak, K.; Handoko, M. L.; Huis in&#39;t Veld, L. F.; Kaul, T.; Kolagasigil-Akdemir, N.; Kusters, M. P. T.; Meijvis, S. C. A.; Oosting, I. J.; Spijker, R.; Bots, M.; Hooft, L.; Verhaar, M.">
<meta name="author" content="">
<link rel="canonical" href="https://trxiv.yorks0n.com/posts/cardiovascular-medicine/">
<link crossorigin="anonymous" href="/assets/css/stylesheet.904bd1e751cdd2a584fa6bed3fa1166dfd8ec9949ebfd0c4d69c5add5e17c23d.css" integrity="sha256-kEvR51HN0qWE&#43;mvtP6EWbf2OyZSev9DE1pxa3V4Xwj0=" rel="preload stylesheet" as="style">
<script defer crossorigin="anonymous" src="/assets/js/highlight.f413e19d0714851f6474e7ee9632408e58ac146fbdbe62747134bea2fa3415e0.js" integrity="sha256-9BPhnQcUhR9kdOfuljJAjlisFG&#43;9vmJ0cTS&#43;ovo0FeA="
    onload="hljs.initHighlightingOnLoad();"></script>
<link rel="icon" href="https://trxiv.yorks0n.com/favicon.ico">
<link rel="icon" type="image/png" sizes="16x16" href="https://trxiv.yorks0n.com/favicon-16x16.png">
<link rel="icon" type="image/png" sizes="32x32" href="https://trxiv.yorks0n.com/favicon-32x32.png">
<link rel="apple-touch-icon" href="https://trxiv.yorks0n.com/apple-touch-icon.png">
<link rel="mask-icon" href="https://trxiv.yorks0n.com/safari-pinned-tab.svg">
<meta name="theme-color" content="#2e2e33">
<meta name="msapplication-TileColor" content="#2e2e33">
<noscript>
    <style>
        #theme-toggle,
        .top-link {
            display: none;
        }

    </style>
    <style>
        @media (prefers-color-scheme: dark) {
            :root {
                --theme: rgb(29, 30, 32);
                --entry: rgb(46, 46, 51);
                --primary: rgb(218, 218, 219);
                --secondary: rgb(155, 156, 157);
                --tertiary: rgb(65, 66, 68);
                --content: rgb(196, 196, 197);
                --hljs-bg: rgb(46, 46, 51);
                --code-bg: rgb(55, 56, 62);
                --border: rgb(51, 51, 51);
            }

            .list {
                background: var(--theme);
            }

            .list:not(.dark)::-webkit-scrollbar-track {
                background: 0 0;
            }

            .list:not(.dark)::-webkit-scrollbar-thumb {
                border-color: var(--theme);
            }
        }

    </style>
</noscript><meta property="og:title" content="cardiovascular medicine" />
<meta property="og:description" content="The persistent underrepresentation of patients with chronic kidney disease in cardiovascular trials: a systematic review and evidence map of exclusion and outcomes
Authors: Colombijn, J. M. T.; Idema, D. L.; van Beem, S.; Blokland, A. M.; van der Braak, K.; Handoko, M. L.; Huis in&#39;t Veld, L. F.; Kaul, T.; Kolagasigil-Akdemir, N.; Kusters, M. P. T.; Meijvis, S. C. A.; Oosting, I. J.; Spijker, R.; Bots, M.; Hooft, L.; Verhaar, M." />
<meta property="og:type" content="article" />
<meta property="og:url" content="https://trxiv.yorks0n.com/posts/cardiovascular-medicine/" /><meta property="article:section" content="posts" />
<meta property="article:published_time" content="2023-07-30T10:36:57+00:00" />
<meta property="article:modified_time" content="2023-07-30T10:36:57+00:00" />

<meta name="twitter:card" content="summary"/>
<meta name="twitter:title" content="cardiovascular medicine"/>
<meta name="twitter:description" content="The persistent underrepresentation of patients with chronic kidney disease in cardiovascular trials: a systematic review and evidence map of exclusion and outcomes
Authors: Colombijn, J. M. T.; Idema, D. L.; van Beem, S.; Blokland, A. M.; van der Braak, K.; Handoko, M. L.; Huis in&#39;t Veld, L. F.; Kaul, T.; Kolagasigil-Akdemir, N.; Kusters, M. P. T.; Meijvis, S. C. A.; Oosting, I. J.; Spijker, R.; Bots, M.; Hooft, L.; Verhaar, M."/>


<script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "BreadcrumbList",
  "itemListElement": [, 
    {
      "@type": "ListItem",
      "position":  2 ,
      "name": "Posts",
      "item": "https://trxiv.yorks0n.com/posts/"
    }, 
    {
      "@type": "ListItem",
      "position":  3 ,
      "name": "cardiovascular medicine",
      "item": "https://trxiv.yorks0n.com/posts/cardiovascular-medicine/"
    }
  ]
}
</script>
<script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "BlogPosting",
  "headline": "cardiovascular medicine",
  "name": "cardiovascular medicine",
  "description": "The persistent underrepresentation of patients with chronic kidney disease in cardiovascular trials: a systematic review and evidence map of exclusion and outcomes\nAuthors: Colombijn, J. M. T.; Idema, D. L.; van Beem, S.; Blokland, A. M.; van der Braak, K.; Handoko, M. L.; Huis in\u0026#39;t Veld, L. F.; Kaul, T.; Kolagasigil-Akdemir, N.; Kusters, M. P. T.; Meijvis, S. C. A.; Oosting, I. J.; Spijker, R.; Bots, M.; Hooft, L.; Verhaar, M.",
  "keywords": [
    
  ],
  "articleBody": " The persistent underrepresentation of patients with chronic kidney disease in cardiovascular trials: a systematic review and evidence map of exclusion and outcomes\nAuthors: Colombijn, J. M. T.; Idema, D. L.; van Beem, S.; Blokland, A. M.; van der Braak, K.; Handoko, M. L.; Huis in't Veld, L. F.; Kaul, T.; Kolagasigil-Akdemir, N.; Kusters, M. P. T.; Meijvis, S. C. A.; Oosting, I. J.; Spijker, R.; Bots, M.; Hooft, L.; Verhaar, M. C.; Vernooij, R. W. M.\nScore: 14.8, Published: 2023-07-20 DOI: 10.1101/2023.07.18.23292848\nBackgroundPatients with chronic kidney disease (CKD) are at high risk for cardiovascular disease, but their systematic underrepresentation in cardiovascular randomised controlled trials (RCTs) limits appropriate evidence to guide cardiovascular risk management (CVRM). This systematic review aims to evaluate trends in the underrepresentation of patients with CKD in cardiovascular RCTs in the past 20 years and highlight evidence gaps for CVRM medications in this population. MethodsA systematic search was conducted in ClinicalTrials.gov from its inception in 2000 until October 2021, targeting RCTs evaluating the efficacy of CVRM medications on mortality, cardiovascular disease, and kidney failure in adults with cardiovascular disease or one or more cardiovascular risk factors. Two reviewers independently screened references and extracted data. Outcomes were the exclusion rate of patients with CKD over time and an evidence map of studies reporting results for this population. ResultsIn total, 1194 RCTs involving 2,207,677 participants were included. Since 2000, the percentage of cardiovascular RCTs that exclude patients with CKD has increased from 66% to 79% (74% overall, 884 RCTs). In 73% of RCTs, more patients were excluded than anticipated on safety grounds (63% without dose adjustment necessary and 79% of RCTs with dose adjustment necessary). In total, 158 RCTs (13%) reported results patients with CKD separately (e.g. in subgroup analyses). Significant evidence gaps exist for most CVRM interventions for patients with CKD, particularly for those with CKD stage 4-5. For patients with an eGFR \u003c30 ml/min/1.73m2, 23 RCTs reported results, for dialysis patients 15 RCTs, and for kidney transplant patients only 1 RCT. ConclusionThe underrepresentation of patients with CKD in cardiovascular RCTs has not improved in the past two decades and three-quarters of RCTs excluded more patients than expected on safety grounds. A lack of RCTs that report results for patients with CKD has resulted in significant evidence gaps for most CVRM medications in all subgroups of patients with CKD, in particular for those with CKD stage 4-5. Primary funding sourceDutch Heart Foundation, 2020B008 RECONNEXT RegistrationPROSPERO (CRD42022296746)\nA multidisciplinary assessment of ChatGPTs knowledge of amyloidosis\nAuthors: King, R. C.; Samaan, J. S.; Yeo, Y. H.; Kunkel, D. C.; Habib, A. A.; Ghashghaei, R.\nScore: 3.9, Published: 2023-07-23 DOI: 10.1101/2023.07.17.23292780\nAmyloidosis is a rare, multisystem disease with several subtypes including AA (secondary), AL (amyloid light chain), and ATTR (transthyretin amyloidosis). In addition to variable symptoms and multidisciplinary management, amyloidosis being a rare disease further contributes to patients being at risk for decreased health literacy regarding their condition. Increased access to education materials containing simple, plain language may bridge literacy gaps and improve outcomes for patients with rare diseases such as amyloidosis. The large language model (LLM), Chat Generative Pre-Trained Transformer (ChatGPT), may be a powerful tool for improving the availability of accurate and easy to understand education materials. Amyloidosis-related questions from cardiology, gastroenterology, and neurology were sourced from esteemed medical societies and institutions along with amyloidosis Facebook support groups and inputted into ChatGPT-3.5 and GPT-4. Answers were graded on 4-point scale with both models responding to the majority of questions with either \"comprehensive\" or \"correct but inadequate\" answers with only 1 (1.2%) answer by GPT-3.5 graded as \"completely inaccurate\". When assessing reproducibility, GPT-3.5 scored reliably on more than 83.3% of responses, while GPT-4 produced above 98.2% consistent answers. Our findings show that ChatGPT can potentially serve as a supplemental tool in disseminating vital health education to patients living with amyloidosis.\nDeciphering the genetic architecture of atrial fibrillation offers insights into disease prediction, pathophysiology and downstream sequelae\nAuthors: Yuan, S.; Li, Y.; Wang, L.; XU, F.; Chen, J.; Levin, M.; Xiong, Y.; Voight, B. F.; Damrauer, S. M.; Gill, D.; Burgess, S.; Akesson, A.; Michaelsson, K.; Li, X.; Shen, X.; Larsson, S. C.\nScore: 1.2, Published: 2023-07-25 DOI: 10.1101/2023.07.20.23292938\nAimsThe study aimed to discover novel genetic loci for atrial fibrillation (AF), explore the shared genetic etiologies between AF and other cardiovascular and cardiometabolic traits, and uncover AF pathogenesis using Mendelian randomization analysis. Methods and resultsWe conducted a genome-wide association study meta-analysis including 109,787 AF cases and 1,165,920 controls of European ancestry and identified 215 loci, among which 91 were novel. We performed Genomic Structural Equation Modeling analysis between AF and four cardiovascular comorbidities (coronary artery disease, ischemic stroke, heart failure, and vneous thromboembolism) and found 189 loci shared across these diseases as well as a universal genetic locus shared by atherosclerotic outcomes (i.e., rs1537373 near CDKN2B). Three genetic loci (rs10740129 near JMJD1C, rs2370982 near NRXN3, and rs9931494 near FTO) were associated with AF and cardiometabolic traits. A polygenic risk score derived from this genome-wide meta-analysis was associated with AF risk (odds ratio 2.36, 95% confidence interval 2.31-2.41 per standard deviation increase) in the UK biobank. This score, combined with age, sex, and basic clinical features, predicted AF risk (AUC 0.784, 95% CI 0.781-0.787) in Europeans. Phenome-wide association analysis of the polygenic risk score identified many AF-related comorbidities of the circulatory, endocrine, and respiratory systems. Phenome-wide and multi-omic Mendelian randomization analyses identified associations of blood lipids and pressure, diabetes, insomnia, obesity, short sleep, and smoking, 27 blood proteins, one gut microbe (genus.Catenibacterium), and 11 blood metabolites with risk to AF. ConclusionsThis genome-wide association study and trans-omic Mendelian randomization analysis provides insights into disease risk prediction, pathophysiology and downstream sequelae.\n",
  "wordCount" : "946",
  "inLanguage": "en",
  "datePublished": "2023-07-30T10:36:57Z",
  "dateModified": "2023-07-30T10:36:57Z",
  "mainEntityOfPage": {
    "@type": "WebPage",
    "@id": "https://trxiv.yorks0n.com/posts/cardiovascular-medicine/"
  },
  "publisher": {
    "@type": "Organization",
    "name": "TRxiv2",
    "logo": {
      "@type": "ImageObject",
      "url": "https://trxiv.yorks0n.com/favicon.ico"
    }
  }
}
</script>
</head>

<body class="" id="top">
<script>
    if (localStorage.getItem("pref-theme") === "dark") {
        document.body.classList.add('dark');
    } else if (localStorage.getItem("pref-theme") === "light") {
        document.body.classList.remove('dark')
    } else if (window.matchMedia('(prefers-color-scheme: dark)').matches) {
        document.body.classList.add('dark');
    }

</script>

<header class="header">
    <nav class="nav">
        <div class="logo">
            <a href="https://trxiv.yorks0n.com" accesskey="h" title="TRxiv2 (Alt + H)">TRxiv2</a>
            <div class="logo-switches">
                <button id="theme-toggle" accesskey="t" title="(Alt + T)">
                    <svg id="moon" xmlns="http://www.w3.org/2000/svg" width="24" height="18" viewBox="0 0 24 24"
                        fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round"
                        stroke-linejoin="round">
                        <path d="M21 12.79A9 9 0 1 1 11.21 3 7 7 0 0 0 21 12.79z"></path>
                    </svg>
                    <svg id="sun" xmlns="http://www.w3.org/2000/svg" width="24" height="18" viewBox="0 0 24 24"
                        fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round"
                        stroke-linejoin="round">
                        <circle cx="12" cy="12" r="5"></circle>
                        <line x1="12" y1="1" x2="12" y2="3"></line>
                        <line x1="12" y1="21" x2="12" y2="23"></line>
                        <line x1="4.22" y1="4.22" x2="5.64" y2="5.64"></line>
                        <line x1="18.36" y1="18.36" x2="19.78" y2="19.78"></line>
                        <line x1="1" y1="12" x2="3" y2="12"></line>
                        <line x1="21" y1="12" x2="23" y2="12"></line>
                        <line x1="4.22" y1="19.78" x2="5.64" y2="18.36"></line>
                        <line x1="18.36" y1="5.64" x2="19.78" y2="4.22"></line>
                    </svg>
                </button>
            </div>
        </div>
        <ul id="menu">
        </ul>
    </nav>
</header>
<main class="main">
<article class="post-single">
  <header class="post-header">
    
    <h1 class="post-title">
      cardiovascular medicine
    </h1>
    <div class="post-meta"><span>updated on July 30, 2023</span>

</div>
  </header> 
  <div class="post-content"><div class="accordion accordion-flush" id="accordionFlushExample"><div class="accordion-item">
    <h3 class="accordion-header" id="flush-heading10.1101/2023.07.18.23292848">
      <button class="accordion-button collapsed" type="button" data-bs-toggle="collapse" data-bs-target="#flush-collapse10.1101/2023.07.18.23292848" aria-expanded="false" aria-controls="flush-collapse10.1101/2023.07.18.23292848">
        <p class="paperTitle">The persistent underrepresentation of patients with chronic kidney disease in cardiovascular trials: a systematic review and evidence map of exclusion and outcomes</p>
      </button>
    </h3>
    <div id="flush-collapse10.1101/2023.07.18.23292848" class="accordion-collapse collapse" aria-labelledby="flush-heading10.1101/2023.07.18.23292848" data-bs-parent="#accordionFlushExample">
      <div class="accordion-body">
        <p class="author">Authors: Colombijn, J. M. T.; Idema, D. L.; van Beem, S.; Blokland, A. M.; van der Braak, K.; Handoko, M. L.; Huis in&#39;t Veld, L. F.; Kaul, T.; Kolagasigil-Akdemir, N.; Kusters, M. P. T.; Meijvis, S. C. A.; Oosting, I. J.; Spijker, R.; Bots, M.; Hooft, L.; Verhaar, M. C.; Vernooij, R. W. M.</p>
        <p class="info">Score: 14.8, Published: 2023-07-20 </p>
        <p class="info">DOI: <a href='https://doi.org/10.1101/2023.07.18.23292848' target='https://doi.org/10.1101/2023.07.18.23292848'> 10.1101/2023.07.18.23292848</a></p>
        <p class="abstract">BackgroundPatients with chronic kidney disease (CKD) are at high risk for cardiovascular disease, but their systematic underrepresentation in cardiovascular randomised controlled trials (RCTs) limits appropriate evidence to guide cardiovascular risk management (CVRM). This systematic review aims to evaluate trends in the underrepresentation of patients with CKD in cardiovascular RCTs in the past 20 years and highlight evidence gaps for CVRM medications in this population.

MethodsA systematic search was conducted in ClinicalTrials.gov from its inception in 2000 until October 2021, targeting RCTs evaluating the efficacy of CVRM medications on mortality, cardiovascular disease, and kidney failure in adults with cardiovascular disease or one or more cardiovascular risk factors. Two reviewers independently screened references and extracted data. Outcomes were the exclusion rate of patients with CKD over time and an evidence map of studies reporting results for this population.

ResultsIn total, 1194 RCTs involving 2,207,677 participants were included. Since 2000, the percentage of cardiovascular RCTs that exclude patients with CKD has increased from 66% to 79% (74% overall, 884 RCTs). In 73% of RCTs, more patients were excluded than anticipated on safety grounds (63% without dose adjustment necessary and 79% of RCTs with dose adjustment necessary). In total, 158 RCTs (13%) reported results patients with CKD separately (e.g. in subgroup analyses). Significant evidence gaps exist for most CVRM interventions for patients with CKD, particularly for those with CKD stage 4-5. For patients with an eGFR &lt;30 ml/min/1.73m2, 23 RCTs reported results, for dialysis patients 15 RCTs, and for kidney transplant patients only 1 RCT.

ConclusionThe underrepresentation of patients with CKD in cardiovascular RCTs has not improved in the past two decades and three-quarters of RCTs excluded more patients than expected on safety grounds. A lack of RCTs that report results for patients with CKD has resulted in significant evidence gaps for most CVRM medications in all subgroups of patients with CKD, in particular for those with CKD stage 4-5.

Primary funding sourceDutch Heart Foundation, 2020B008 RECONNEXT

RegistrationPROSPERO (CRD42022296746)</p>
      </div>
    </div>
  </div><div class="accordion-item">
    <h3 class="accordion-header" id="flush-heading10.1101/2023.07.17.23292780">
      <button class="accordion-button collapsed" type="button" data-bs-toggle="collapse" data-bs-target="#flush-collapse10.1101/2023.07.17.23292780" aria-expanded="false" aria-controls="flush-collapse10.1101/2023.07.17.23292780">
        <p class="paperTitle">A multidisciplinary assessment of ChatGPTs knowledge of amyloidosis</p>
      </button>
    </h3>
    <div id="flush-collapse10.1101/2023.07.17.23292780" class="accordion-collapse collapse" aria-labelledby="flush-heading10.1101/2023.07.17.23292780" data-bs-parent="#accordionFlushExample">
      <div class="accordion-body">
        <p class="author">Authors: King, R. C.; Samaan, J. S.; Yeo, Y. H.; Kunkel, D. C.; Habib, A. A.; Ghashghaei, R.</p>
        <p class="info">Score: 3.9, Published: 2023-07-23 </p>
        <p class="info">DOI: <a href='https://doi.org/10.1101/2023.07.17.23292780' target='https://doi.org/10.1101/2023.07.17.23292780'> 10.1101/2023.07.17.23292780</a></p>
        <p class="abstract">Amyloidosis is a rare, multisystem disease with several subtypes including AA (secondary), AL (amyloid light chain), and ATTR (transthyretin amyloidosis). In addition to variable symptoms and multidisciplinary management, amyloidosis being a rare disease further contributes to patients being at risk for decreased health literacy regarding their condition. Increased access to education materials containing simple, plain language may bridge literacy gaps and improve outcomes for patients with rare diseases such as amyloidosis. The large language model (LLM), Chat Generative Pre-Trained Transformer (ChatGPT), may be a powerful tool for improving the availability of accurate and easy to understand education materials. Amyloidosis-related questions from cardiology, gastroenterology, and neurology were sourced from esteemed medical societies and institutions along with amyloidosis Facebook support groups and inputted into ChatGPT-3.5 and GPT-4. Answers were graded on 4-point scale with both models responding to the majority of questions with either &#34;comprehensive&#34; or &#34;correct but inadequate&#34; answers with only 1 (1.2%) answer by GPT-3.5 graded as &#34;completely inaccurate&#34;. When assessing reproducibility, GPT-3.5 scored reliably on more than 83.3% of responses, while GPT-4 produced above 98.2% consistent answers. Our findings show that ChatGPT can potentially serve as a supplemental tool in disseminating vital health education to patients living with amyloidosis.</p>
      </div>
    </div>
  </div><div class="accordion-item">
    <h3 class="accordion-header" id="flush-heading10.1101/2023.07.20.23292938">
      <button class="accordion-button collapsed" type="button" data-bs-toggle="collapse" data-bs-target="#flush-collapse10.1101/2023.07.20.23292938" aria-expanded="false" aria-controls="flush-collapse10.1101/2023.07.20.23292938">
        <p class="paperTitle">Deciphering the genetic architecture of atrial fibrillation offers insights into disease prediction, pathophysiology and downstream sequelae</p>
      </button>
    </h3>
    <div id="flush-collapse10.1101/2023.07.20.23292938" class="accordion-collapse collapse" aria-labelledby="flush-heading10.1101/2023.07.20.23292938" data-bs-parent="#accordionFlushExample">
      <div class="accordion-body">
        <p class="author">Authors: Yuan, S.; Li, Y.; Wang, L.; XU, F.; Chen, J.; Levin, M.; Xiong, Y.; Voight, B. F.; Damrauer, S. M.; Gill, D.; Burgess, S.; Akesson, A.; Michaelsson, K.; Li, X.; Shen, X.; Larsson, S. C.</p>
        <p class="info">Score: 1.2, Published: 2023-07-25 </p>
        <p class="info">DOI: <a href='https://doi.org/10.1101/2023.07.20.23292938' target='https://doi.org/10.1101/2023.07.20.23292938'> 10.1101/2023.07.20.23292938</a></p>
        <p class="abstract">AimsThe study aimed to discover novel genetic loci for atrial fibrillation (AF), explore the shared genetic etiologies between AF and other cardiovascular and cardiometabolic traits, and uncover AF pathogenesis using Mendelian randomization analysis.

Methods and resultsWe conducted a genome-wide association study meta-analysis including 109,787 AF cases and 1,165,920 controls of European ancestry and identified 215 loci, among which 91 were novel. We performed Genomic Structural Equation Modeling analysis between AF and four cardiovascular comorbidities (coronary artery disease, ischemic stroke, heart failure, and vneous thromboembolism) and found 189 loci shared across these diseases as well as a universal genetic locus shared by atherosclerotic outcomes (i.e., rs1537373 near CDKN2B). Three genetic loci (rs10740129 near JMJD1C, rs2370982 near NRXN3, and rs9931494 near FTO) were associated with AF and cardiometabolic traits. A polygenic risk score derived from this genome-wide meta-analysis was associated with AF risk (odds ratio 2.36, 95% confidence interval 2.31-2.41 per standard deviation increase) in the UK biobank. This score, combined with age, sex, and basic clinical features, predicted AF risk (AUC 0.784, 95% CI 0.781-0.787) in Europeans. Phenome-wide association analysis of the polygenic risk score identified many AF-related comorbidities of the circulatory, endocrine, and respiratory systems. Phenome-wide and multi-omic Mendelian randomization analyses identified associations of blood lipids and pressure, diabetes, insomnia, obesity, short sleep, and smoking, 27 blood proteins, one gut microbe (genus.Catenibacterium), and 11 blood metabolites with risk to AF.

ConclusionsThis genome-wide association study and trans-omic Mendelian randomization analysis provides insights into disease risk prediction, pathophysiology and downstream sequelae.</p>
      </div>
    </div>
  </div>
</div>









<script src="/js/bundle.min.js" defer></script>



  </div>

  <footer class="post-footer">
    <ul class="post-tags">
    </ul>
  </footer>
</article>
    </main>
    
<footer class="footer">
    <span>&copy; 2023 <a href="https://trxiv.yorks0n.com">TRxiv2</a></span>
    <span>
        · Made by Yorkson
    </span>
</footer>
<a href="#top" aria-label="go to top" title="Go to Top (Alt + G)" class="top-link" id="top-link" accesskey="g">
    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 12 6" fill="currentColor">
        <path d="M12 6H0l6-6z" />
    </svg>
</a>

<script>
    let menu = document.getElementById('menu')
    if (menu) {
        menu.scrollLeft = localStorage.getItem("menu-scroll-position");
        menu.onscroll = function () {
            localStorage.setItem("menu-scroll-position", menu.scrollLeft);
        }
    }

    document.querySelectorAll('a[href^="#"]').forEach(anchor => {
        anchor.addEventListener("click", function (e) {
            e.preventDefault();
            var id = this.getAttribute("href").substr(1);
            if (!window.matchMedia('(prefers-reduced-motion: reduce)').matches) {
                document.querySelector(`[id='${decodeURIComponent(id)}']`).scrollIntoView({
                    behavior: "smooth"
                });
            } else {
                document.querySelector(`[id='${decodeURIComponent(id)}']`).scrollIntoView();
            }
            if (id === "top") {
                history.replaceState(null, null, " ");
            } else {
                history.pushState(null, null, `#${id}`);
            }
        });
    });

</script>
<script>
    var mybutton = document.getElementById("top-link");
    window.onscroll = function () {
        if (document.body.scrollTop > 800 || document.documentElement.scrollTop > 800) {
            mybutton.style.visibility = "visible";
            mybutton.style.opacity = "1";
        } else {
            mybutton.style.visibility = "hidden";
            mybutton.style.opacity = "0";
        }
    };

</script>
<script>
    document.getElementById("theme-toggle").addEventListener("click", () => {
        if (document.body.className.includes("dark")) {
            document.body.classList.remove('dark');
            localStorage.setItem("pref-theme", 'light');
        } else {
            document.body.classList.add('dark');
            localStorage.setItem("pref-theme", 'dark');
        }
    })

</script>
</body>

</html>
